Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""immunogenicity"" wg kryterium: Temat


Tytuł:
Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Autorzy:
Sirisreetreerux S; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand. .
Porntharukchareon T; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Dechates B; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Rangsrisaeneepitak V; Division of Endocrine and Metabolism, Department of Medicine, Burapha Hospital, Saen Suk, Mueang Chonburi, 20131, Thailand.
Therawit P; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Worawitchawong S; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Sornsamdang G; Central Laboratory Center, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Soonklang K; Center of Learning and Research in Celebration of HRH Princess Chulabhorn 60th Birthday Anniversary, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Tawinprai K; Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, 906 Thung Song Hong, Lak Si, Bangkok, 10210, Thailand.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jul 21; Vol. 13 (1), pp. 11798. Date of Electronic Publication: 2023 Jul 21.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
ChAdOx1 nCoV-19*/administration & dosage
ChAdOx1 nCoV-19*/immunology
ChAdOx1 nCoV-19*/therapeutic use
COVID-19*/complications
COVID-19*/immunology
COVID-19*/prevention & control
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/immunology
Immunogenicity, Vaccine*/immunology
Female ; Humans ; Male ; Middle Aged ; Cohort Studies ; Prospective Studies ; SARS-CoV-2 ; Southeast Asian People ; Thailand/epidemiology ; Aged
Czasopismo naukowe
Tytuł:
Decision nears for fall coronavirus vaccine.
Autorzy:
Couzin-Frankel J
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2023 May 26; Vol. 380 (6647), pp. 784. Date of Electronic Publication: 2023 May 25.
Typ publikacji:
Wiadomości
MeSH Terms:
COVID-19 Vaccines*/immunology
SARS-CoV-2*/immunology
Immunogenicity, Vaccine*
Immunization, Secondary*
COVID-19*
Humans ; Antibodies, Viral/immunology ; Vaccination
SCR Protocol:
COVID-19 vaccine booster shot
Periodyk
Tytuł:
Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.
Autorzy:
Kingston NJ; Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia.; School of Molecular and Cellular Biology, Faculty of Biological Sciences, Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
Walsh R; Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Hammond R; Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Joe CCD; School of Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, VIC 3001, Australia.; Commonwealth Scientific and Industrial Research Organisation, Clayton, VIC 3169, Australia.; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Lovrecz G; Commonwealth Scientific and Industrial Research Organisation, Clayton, VIC 3169, Australia.
Locarnini S; Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Netter HJ; Victorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.; School of Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, VIC 3001, Australia.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Jan 23; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B Surface Antigens*/genetics
Hepatitis B Surface Antigens*/immunology
Immunogenicity, Vaccine*/genetics
Immunogenicity, Vaccine*/immunology
Malaria Vaccines*/genetics
Malaria Vaccines*/immunology
Plasmodium falciparum*/genetics
Plasmodium falciparum*/immunology
Vaccines, Virus-Like Particle*/genetics
Vaccines, Virus-Like Particle*/immunology
Animals ; Mice ; Epitopes/genetics ; Epitopes/immunology ; Malaria/prevention & control ; Mice, Inbred BALB C ; Models, Animal ; Vaccination
Czasopismo naukowe
Tytuł:
Mosaic quadrivalent influenza vaccine single nanoparticle characterization.
Autorzy:
Yang RS; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Traver M; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Barefoot N; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Stephens T; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Alabanza C; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Manzella-Lapeira J; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Zou G; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Wolff J; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Li Y; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Resto M; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Shadrick W; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Yang Y; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Ivleva VB; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Tsybovsky Y; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Carlton K; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Brzostowski J; Twinbrook Imaging Facility, LIG, NIAID, NIH, Gaithersburg, MD, USA.
Gall JG; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA.
Lei QP; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 9 West Watkins Mill Rd., Gaithersburg, MD, 20878, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 24; Vol. 14 (1), pp. 4534. Date of Electronic Publication: 2024 Feb 24.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza Vaccines*
Influenza, Human*/prevention & control
Nanoparticles*/chemistry
Humans ; Antibodies, Viral ; Hemagglutinin Glycoproteins, Influenza Virus ; Hemagglutinins ; Immunogenicity, Vaccine ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine.
Autorzy:
Handabile C; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Ohno M; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; One Health Research Center, Hokkaido University, Sapporo, Japan.
Sekiya T; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Nomura N; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Kawakita T; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Vaccine Immunology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Kawahara M; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Endo M; KM Biologics Co. Ltd, Kumamoto, Japan.
Nishimura T; KM Biologics Co. Ltd, Kumamoto, Japan.
Okumura M; KM Biologics Co. Ltd, Kumamoto, Japan.
Toba S; Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, Toyonaka, Japan.; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Sasaki M; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Orba Y; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Chua BY; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Rowntree LC; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Nguyen THO; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Shingai M; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Division of Vaccine Immunology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Sato A; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; Shionogi Pharmaceutical Research Center, Shionogi & Company, Limited, Toyonaka, Japan.; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Sawa H; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; One Health Research Center, Hokkaido University, Sapporo, Japan.; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Ogasawara K; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Kedzierska K; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.; Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Kida H; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan. .; Division of Biologics Development, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. .; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. .; Division of Vaccine Immunology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 20; Vol. 14 (1), pp. 4204. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza, Human*
Influenza Vaccines*
Influenza A Virus, H1N1 Subtype*
COVID-19*/prevention & control
Animals ; Mice ; Humans ; COVID-19 Vaccines ; Antibodies, Viral ; SARS-CoV-2 ; Vaccination/methods ; Virion ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus.
Autorzy:
Piyaphanee N; Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Charuvanij S; Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Thepveera S; Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Toh ZQ; Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.; Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Licciardi PV; Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville, VIC, Australia.; Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia.
Pattaragarn A; Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Wongprompitak P; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Boonnak K; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pheerapanyawaranun C; Siriraj Institute of Clinical Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chokephaibulkit K; Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.; Siriraj Institute of Clinical Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Apr; Vol. 33 (5), pp. 450-461. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Lupus Erythematosus, Systemic*/drug therapy
Humans ; Adolescent ; BNT162 Vaccine ; COVID-19 Vaccines/adverse effects ; Symptom Flare Up ; Prednisolone ; Immunosuppressive Agents/adverse effects ; Immunoglobulin G ; Antibodies, Viral ; Vaccination ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Increased bacterial taxonomic and functional diversity is associated with impaired rotavirus vaccine immunogenicity in infants from India and Malawi.
Autorzy:
Cunningham-Oakes E; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. .; NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK. .
Bronowski C; Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Chinyama E; Virology Research Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, 312225, Malawi.
Jere KC; NIHR Health Protection Research Unit in Gastrointestinal Infections, Liverpool, UK.; Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; Virology Research Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, 312225, Malawi.; Department of Medical Laboratory Sciences, School of Life Sciences and Allied Health Professions, Kamuza University of Health Sciences, Blantyre, 312225, Malawi.
Sindhu KNC; Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India.
Kang G; Wellcome Trust Research Laboratory, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, Tamil Nadu, India.
Iturriza-Gómara M; Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.; Centre for Vaccine Innovation and Access, Program for Appropriate Technology in Health (PATH), 1218, Geneva, Switzerland.
Darby AC; Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Parker EPK; The Vaccine Centre, Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
Pokaż więcej
Źródło:
BMC microbiology [BMC Microbiol] 2023 Nov 18; Vol. 23 (1), pp. 354. Date of Electronic Publication: 2023 Nov 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Rotavirus*/genetics
Rotavirus Vaccines*
Rotavirus Infections*/prevention & control
Humans ; Infant ; Malawi ; Prospective Studies ; Immunogenicity, Vaccine ; India ; Vaccines, Attenuated ; Antibodies, Viral
Czasopismo naukowe
Tytuł:
Humoral immunogenicity assessment after receiving three types of SARS-CoV-2 vaccine.
Autorzy:
Najafi N; Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran.
Soleimanjahi H; Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran. SOLEIM_.
Moghaddam-Banaem L; Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Raoufy MR; Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Shahali S; Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Kazemnejad A; Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Nasiri Z; Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-331, Tehran, Iran.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 18; Vol. 13 (1), pp. 20213. Date of Electronic Publication: 2023 Nov 18.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19 Vaccines*
COVID-19*/prevention & control
Adult ; Humans ; Longitudinal Studies ; Prospective Studies ; SARS-CoV-2 ; Vaccination ; Antibodies, Viral ; Immunoglobulin G ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Exploring the immunogenicity of an insect-specific virus vectored Zika vaccine candidate.
Autorzy:
Tanelus M; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
López K; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Smith S; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Muller JA; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Porier DL; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Auguste DI; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Stone WB; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Paulson SL; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA.
Auguste AJ; Department of Entomology, College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA. .; Center for Emerging, Zoonotic, and Arthropod-Borne Pathogens, Virginia Polytechnic Institute and State University, Blacksburg, VA, 24061, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 15; Vol. 13 (1), pp. 19948. Date of Electronic Publication: 2023 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Zika Virus*/genetics
Zika Virus Infection*
Viral Vaccines*
Humans ; Animals ; Mice ; Chlorocebus aethiops ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.
Autorzy:
Chaiwarith R; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. .
Winichakoon P; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Salee P; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Sudjaritruk T; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.; Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Wipasa J; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.
Chawansuntati K; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, 50200, Thailand.
Yasri S; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Thongwitokomarn H; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Krasaewes K; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Ruangsirinusorn S; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Praparattanapan J; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Solai N; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Nuket K; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Boonmee D; Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Chaichana O; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.; Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Mueangmo O; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.; Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Saheng J; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.; Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Wongjak W; Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.; Clinical and Molecular Epidemiology of Emerging and Re-Emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 13; Vol. 13 (1), pp. 19736. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Immunogenicity, Vaccine ; Prospective Studies ; SARS-CoV-2 ; Vaccines
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Autorzy:
Eybpoosh S; Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Biglari A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sorouri R; IPI Directorate, Pasteur Institute of Iran, Tehran, Iran.; Department of Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ashrafian F; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
Sadat Larijani M; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
Verez-Bencomo V; Finlay Vaccine Institute, Havana, Cuba.
Toledo-Romani ME; Pedro Kourí Tropical Medicine Institute, Havana, Cuba.
Valenzuela Silva C; Cybernetics, Mathematics and Physics Institute, Havana, Cuba.
Salehi-Vaziri M; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
Dahmardeh S; Vaccination Department, Pasteur Institute of Iran, Tehran, Iran.
Doroud D; Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran, Iran.
Banifazl M; Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran.
Mostafavi E; Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
Bavand A; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
Ramezani A; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 Nov 01; Vol. 19 (11), pp. e1011744. Date of Electronic Publication: 2023 Nov 01 (Print Publication: 2023).
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/prevention & control
Humans ; Immunization ; Antibodies, Neutralizing ; Immunoglobulin G ; Antibodies, Viral ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Autorzy:
Kulkarni PS; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India. .
Gunale B; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Kohli S; Hamdard Institute of Medical Sciences and Research, New Delhi, India.
Lalwani S; Bharati Vidyapeeth Deemed University Medical College and Hospital, Pune, India.
Tripathy S; Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, India.
Kar S; Kalinga Institute of Medical Sciences, Bhubaneswar, India.
Raut S; Noble Hospital Pvt. Ltd, Pune, India.
Kulkarni P; JSS Academy of Higher Education and Research, Mysore, India.
Apte A; KEM Hospital Research Centre-Community Health Research Unit, P.O. Manchar, Pune, India.
Bavdekar A; KEM Hospital Research Centre-Community Health Research Unit, P.O. Manchar, Pune, India.
Bhalla HL; All India Institute of Medical Sciences (AIIMS), Gorakhpur, India.
Plested JS; Novavax, Inc., Gaithersburg, USA.
Cloney-Clark S; Novavax, Inc., Gaithersburg, USA.
Zhu M; Novavax, Inc., Gaithersburg, USA.
Kalkeri R; Novavax, Inc., Gaithersburg, USA.
Pryor M; 360Biolabs, Melbourne, Australia.
Hamilton S; 360Biolabs, Melbourne, Australia.
Thakar M; ICMR - National AIDS Research Institute, Pune, India.
Sannidhi RS; PPD, Benguluru, India.
Baranwal P; PPD, Benguluru, India.
Bhamare C; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Dharmadhikari A; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Gupta M; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Poonawalla CS; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Shaligram U; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Kapse D; Serum Institute of India Pvt Ltd, Manjari (Bk), Administration Building, Poonawalla Biotechnology Park SEZ, Taluka Haveli, Pune, India.
Pokaż więcej
Corporate Authors:
COVOVAX-Booster Study Group
Źródło:
Scientific reports [Sci Rep] 2023 Oct 03; Vol. 13 (1), pp. 16579. Date of Electronic Publication: 2023 Oct 03.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
Vaccines*
Adult ; Humans ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 ; Spike Glycoprotein, Coronavirus ; Antibodies, Neutralizing ; Immunoglobulin G ; Antibodies, Viral ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study.
Autorzy:
Yegorov S; Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada. .; School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan. .
Kadyrova I; Research Centre, Karaganda Medical University, Karaganda, Kazakhstan. .
Negmetzhanov B; School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan.; National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan.
Kolesnikova Y; Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Kolesnichenko S; Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Korshukov I; Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Baiken Y; School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan.; National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan.; School of Engineering and Digital Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan.
Matkarimov B; National Laboratory Astana, Centre for Life Sciences, Nazarbayev University, Nur-Sultan, Kazakhstan.
Miller MS; Department of Biochemistry and Biomedical Sciences, Michael G. DeGroote Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Hortelano GH; School of Sciences and Humanities, Nazarbayev University, Nur-Sultan, Kazakhstan.
Babenko D; Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Aug 01; Vol. 12 (1), pp. 13207. Date of Electronic Publication: 2022 Aug 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
Immunogenicity, Vaccine*
Antibodies, Viral ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Mucous Membrane ; Prospective Studies ; SARS-CoV-2
Czasopismo naukowe
Tytuł:
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Autorzy:
Vadrevu KM; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India. .
Ganneru B; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Reddy S; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Jogdand H; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Raju D; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Sapkal G; Indian Council of Medical Research-National Institute of Virology, Pune, India.
Yadav P; Indian Council of Medical Research-National Institute of Virology, Pune, India.
Reddy P; Nizam's Institute of Medical Sciences, Hyderabad, India.
Verma S; Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India.
Singh C; All India Institute of Medical Sciences, Patna, India.
Redkar SV; Redkar Hospital, Dargalim, India.
Gillurkar CS; Gillurkar Hospital, Nagpur, India.
Kushwaha JS; Prakhar Hospital, Kanpur, India.
Mohapatra S; SRM Hospital and Research Centre, Kattankulathur, India.
Bhate A; Jeevan Rekha Hospital, Belgaum, India.
Rai SK; All India Institute of Medical Sciences, New Delhi, India.
Ella R; Independent Clinical Development Consultant, Cambridge, USA.
Abraham P; Indian Council of Medical Research-National Institute of Virology, Pune, India.
Prasad S; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Ella K; Bharat Biotech International Limited, Genome Valley, Hyderabad, 500 078, India.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jul 14; Vol. 12 (1), pp. 12038. Date of Electronic Publication: 2022 Jul 14.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
Immunogenicity, Vaccine*
Antibodies, Neutralizing ; Antibodies, Viral ; Humans ; Immunity, Cellular ; Immunity, Humoral ; Immunization, Secondary ; SARS-CoV-2 ; Vaccination ; Vaccines, Inactivated
SCR Disease Name:
COVID-19 breakthrough infections
Czasopismo naukowe
Tytuł:
Adjuvant effects of combination monophosphoryl lipid A and poly I:C on antigen-specific immune responses and protective efficacy of influenza vaccines.
Autorzy:
Le, Chau Thuy Tien (AUTHOR)
Ahn, So Yeon (AUTHOR)
Ho, Thi Len (AUTHOR)
Lee, Jueun (AUTHOR)
Lee, Dong-Ha (AUTHOR)
Hwang, Hye Suk (AUTHOR)
Kang, Sang-Moo (AUTHOR)
Ko, Eun-Ju (AUTHOR)
Pokaż więcej
Źródło:
Scientific Reports. 7/28/2023, Vol. 13 Issue 1, p1-12. 12p.
Czasopismo naukowe
Tytuł:
Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines?
Autorzy:
Merkuleva IA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Shcherbakov DN; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Borgoyakova MB; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Isaeva AA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Nesmeyanova VS; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Volkova NV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Aripov VS; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Shanshin DV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Karpenko LI; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Belenkaya SV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Kazachinskaia EI; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Volosnikova EA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Esina TI; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Sergeev AA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Titova KA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Konyakhina YV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Zaykovskaya AV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Pyankov OV; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Kolosova EA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.; Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia.
Viktorina OE; Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia.
Shelemba AA; Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia.
Rudometov AP; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Ilyichev AA; State Research Center of Virology and Biotechnology 'Vector', Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 May 16; Vol. 14 (5). Date of Electronic Publication: 2022 May 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
Immunogenicity, Vaccine*
Spike Glycoprotein, Coronavirus*/immunology
Animals ; Chickens ; Cricetinae ; Disease Models, Animal ; Ferrets ; Mice ; Mice, Inbred BALB C ; Rabbits ; SARS-CoV-2 ; Vaccines, Subunit/immunology
Czasopismo naukowe
Tytuł:
Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV.
Autorzy:
Tuan JJ; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Zapata H; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Critch-Gilfillan T; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Ryall L; Yale Center for Clinical Investigation, Yale University School of Medicine, New Haven, Connecticut, USA.
Turcotte B; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Mutic S; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Andrews L; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Roh ME; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.
Friedland G; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Barakat L; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Ogbuagu O; Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.; Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Feb; Vol. 23 (2), pp. 178-185. Date of Electronic Publication: 2021 Oct 10.
Typ publikacji:
Journal Article
MeSH Terms:
BNT162 Vaccine*/administration & dosage
HIV Infections*/epidemiology
Immunogenicity, Vaccine*
Spike Glycoprotein, Coronavirus*/immunology
Aged ; Humans ; Qualitative Research
Czasopismo naukowe
Tytuł:
Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study.
Autorzy:
Ohm M; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
van Straalen JW; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
de Joode-Smink G; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
van Montfrans J; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.; Department of Pediatric Infectious Diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
Bartels M; Department of Pediatric Hematology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
van Wildenbeest JG; Department of Pediatric Infectious Diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
Lindemans CA; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Wennink RA; Department of Ophthalmology, University Medical Centre Utrecht, Utrecht, the Netherlands.
de Boer JH; Department of Ophthalmology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Sanders EA; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Verduyn-Lunel FM; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Berbers GA; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
Wulffraat NM; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands.
Jansen MHA; Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands. .
Pokaż więcej
Źródło:
Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2023 Jul 20; Vol. 21 (1), pp. 73. Date of Electronic Publication: 2023 Jul 20.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Meningococcal Infections*/prevention & control
Meningococcal Infections*/chemically induced
Meningococcal Vaccines*/adverse effects
Humans ; Adolescent ; Vaccines, Conjugate/adverse effects ; Immunogenicity, Vaccine ; Prospective Studies ; Antibodies, Bacterial ; Immunoglobulin G
Czasopismo naukowe
Tytuł:
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study.
Autorzy:
Puspitasari M; Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia. .
Sattwika PD; Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.; Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.; Cardiovascular Clinical Research Facility, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Rahari DS; Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Wijaya W; Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Hidayat ARP; Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Kertia N; Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
Purwanto B; Department of Internal Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia.
Thobari JA; Clinical Epidemiology and Biostatistics Unit, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.; Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jul 18; Vol. 13 (1), pp. 11557. Date of Electronic Publication: 2023 Jul 18.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*/prevention & control
COVID-19 Vaccines*/adverse effects
Renal Dialysis*
Humans ; Antibodies, Neutralizing ; Antibodies, Viral ; Immunogenicity, Vaccine ; Immunoglobulin G ; Prospective Studies ; SARS-CoV-2 ; Vaccines, Inactivated/adverse effects
Czasopismo naukowe
Tytuł:
Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19.
Autorzy:
Chang A; Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Harvard Medical School, Boston, MA 02115, USA.
Yu J; Beth Israel Deaconess Medical Center, Center for Virology and Vaccine Research, Harvard Medical School, Boston, MA 02115, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Feb 12; Vol. 14 (2). Date of Electronic Publication: 2022 Feb 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunogenicity, Vaccine*
COVID-19/*prevention & control
Genetic Vectors/*immunology
SARS-CoV-2/*immunology
Viral Vaccines/*genetics
Viral Vaccines/*immunology
Animals ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19 Vaccines/genetics ; COVID-19 Vaccines/immunology ; Clinical Trials as Topic ; Disease Models, Animal ; Immunity, Cellular ; Immunity, Humoral ; Immunity, Innate ; Immunization, Secondary ; Spike Glycoprotein, Coronavirus/genetics ; Vaccination ; Viral Vaccines/classification
Czasopismo naukowe
Tytuł:
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.
Autorzy:
Uprichard SL; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.; Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
O'Brien A; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Evdokimova M; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Rowe CL; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Joyce C; Department of Public Health Sciences, Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL 60153, USA.
Hackbart M; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Cruz-Pulido YE; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Cohen CA; Viral Immunology Branch, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.; The Geneva Foundation, Tacoma, WA 98042, USA.
Rock ML; Viral Immunology Branch, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.; The Geneva Foundation, Tacoma, WA 98042, USA.
Dye JM; Viral Immunology Branch, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.
Kuehnert P; Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA.
Ricks KM; Diagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD 21702, USA.
Casper M; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Linhart L; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Anderson K; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Kirk L; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Maggiore JA; Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Herbert AS; Viral Immunology Branch, Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.
Clark NM; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.; Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Reid GE; Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.; Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Baker SC; Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.; Infectious Disease and Immunology Research Institute, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Feb 10; Vol. 14 (2). Date of Electronic Publication: 2022 Feb 10.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Immunogenicity, Vaccine*
2019-nCoV Vaccine mRNA-1273/*immunology
Antibodies, Viral/*blood
BNT162 Vaccine/*immunology
COVID-19/*prevention & control
SARS-CoV-2/*immunology
Vaccination/*statistics & numerical data
2019-nCoV Vaccine mRNA-1273/administration & dosage ; Adult ; Antibodies, Viral/immunology ; Antibody Formation ; BNT162 Vaccine/administration & dosage ; COVID-19/immunology ; Cohort Studies ; Female ; Humans ; Immunoglobulin G/blood ; Immunoglobulin G/immunology ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
Autorzy:
Citu IM; Department of Internal Medicine I, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Citu C; Department of Obstetrics and Gynecology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Gorun F; Department of Obstetrics and Gynecology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Sas I; Department of Obstetrics and Gynecology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Tomescu L; Department of Obstetrics and Gynecology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Neamtu R; Department of Obstetrics and Gynecology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Motoc A; Department of Anatomy and Embryology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Gorun OM; Department of Obstetrics and Gynecology, Municipal Emergency Clinical Hospital Timisoara, 300202 Timisoara, Romania.
Burlea B; Department of Obstetrics and Gynecology, Municipal Emergency Clinical Hospital Timisoara, 300202 Timisoara, Romania.
Bratosin F; Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, 'Victor Babes' University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Malita D; Department of Radiology, 'Victor Babes' University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Feb 02; Vol. 14 (2). Date of Electronic Publication: 2022 Feb 02.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Immunogenicity, Vaccine*
Ad26COVS1/*immunology
Antibodies, Viral/*blood
BNT162 Vaccine/*immunology
COVID-19/*prevention & control
Pregnancy Trimester, Third/*immunology
Ad26COVS1/administration & dosage ; Adult ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; BNT162 Vaccine/administration & dosage ; Female ; Humans ; Incidence ; Pregnancy ; Pregnancy Outcome ; Pregnant Women ; Prospective Studies ; SARS-CoV-2/immunology ; Young Adult
Czasopismo naukowe
Tytuł:
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac).
Autorzy:
Jeewandara C; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Fernando S; Ministry of Health Sri Lanka, Colombo, Sri Lanka.
Pushpakumara PD; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Ramu ST; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Kamaladasa A; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Gunasekara B; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Aberathna IS; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Kuruppu H; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Ranasinghe T; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Dayarathne S; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Dissanayake O; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Gamalath N; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Ekanayake D; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Jayamali J; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Wijesinghe A; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Dissanayake M; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Somathilake G; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Harvie M; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Danasekara S; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Jayathilaka D; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka.
Wijayatilake HDK; Ministry of Health Sri Lanka, Colombo, Sri Lanka.
Weerasooriya N; Ministry of Health Sri Lanka, Colombo, Sri Lanka.
Kekulandara C; Ministry of Health Sri Lanka, Colombo, Sri Lanka.
Schimanski L; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Rijal P; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Tan TK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Dong T; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Townsend A; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Ogg GS; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Malavige GN; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Nugegoda, Sri Lanka. .; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Feb 02; Vol. 12 (1), pp. 1727. Date of Electronic Publication: 2022 Feb 02.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunization*
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
ChAdOx1 nCoV-19/*administration & dosage
SARS-CoV-2/*immunology
Vaccines, Synthetic/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Angiotensin-Converting Enzyme 2/immunology ; Biomarkers/blood ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Vaccines/immunology ; ChAdOx1 nCoV-19/immunology ; Female ; Humans ; Interferon-gamma/metabolism ; Lymphocytes/immunology ; Lymphocytes/metabolism ; Lymphocytes/virology ; Male ; Middle Aged ; Seroconversion ; Time Factors ; Treatment Outcome ; Vaccines, Synthetic/immunology ; Young Adult
Czasopismo naukowe
Tytuł:
Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.
Autorzy:
Scurr MJ; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.; ImmunoServ Ltd, Cardiff, UK.
Zelek WM; School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.; UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK.
Lippiatt G; ImmunoServ Ltd, Cardiff, UK.
Somerville M; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Burnell SEA; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Capitani L; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Davies K; Radyr Medical Centre, Cardiff, UK.
Lawton H; Radyr Medical Centre, Cardiff, UK.
Tozer T; Department of Gastroenterology & Hepatology, University Hospital of Wales, Cardiff, UK.
Rees T; Department of Gastroenterology & Hepatology, University Hospital of Wales, Cardiff, UK.
Roberts K; Department of Gastroenterology & Hepatology, University Hospital of Wales, Cardiff, UK.
Evans M; Velindre Cancer Centre, Cardiff, UK.
Jackson A; Velindre Cancer Centre, Cardiff, UK.
Young C; Velindre Cancer Centre, Cardiff, UK.
Fairclough L; School of Life Sciences, University of Nottingham, Nottingham, UK.
Tighe P; School of Life Sciences, University of Nottingham, Nottingham, UK.
Wills M; Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Westwell AD; School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.
Morgan BP; School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.; UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK.
Gallimore A; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.; School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.
Godkin A; Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.; School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.; Department of Gastroenterology & Hepatology, University Hospital of Wales, Cardiff, UK.
Pokaż więcej
Źródło:
Immunology [Immunology] 2022 Feb; Vol. 165 (2), pp. 250-259. Date of Electronic Publication: 2021 Dec 06.
Typ publikacji:
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunity, Cellular*
Immunogenicity, Vaccine*
Vaccination*
COVID-19/*immunology
COVID-19 Vaccines/*immunology
Carrier State/*immunology
SARS-CoV-2/*immunology
Th1 Cells/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; COVID-19/prevention & control ; Female ; Humans ; Interferon-gamma/immunology ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients.
Autorzy:
Crane C; Department of Pediatrics, Division of Pediatric Nephrology, University of California At San Diego and Rady Children's Hospital, 3020 Children's Way MC 5173, San Diego, CA, 92123, USA. .
Phebus E; Kidney Transplant Program, Rady Children's Hospital, San Diego, CA, USA.
Ingulli E; Department of Pediatrics, Division of Pediatric Nephrology, University of California At San Diego and Rady Children's Hospital, 3020 Children's Way MC 5173, San Diego, CA, 92123, USA.
Pokaż więcej
Źródło:
Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2022 Feb; Vol. 37 (2), pp. 449-453. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Immunogenicity, Vaccine*
Kidney Transplantation*
Transplant Recipients*
COVID-19/*immunology
COVID-19 Vaccines/*pharmacology
Adolescent ; Antibodies, Viral ; BNT162 Vaccine ; COVID-19/complications ; COVID-19 Vaccines/administration & dosage ; Child ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; RNA, Messenger ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł:
BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
Autorzy:
Tangie E; Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Health Sciences Faculty, University of Cape Town, Observatory, South Africa.
Walters A; Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Health Sciences Faculty, University of Cape Town, Observatory, South Africa.
Hsu NJ; Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Health Sciences Faculty, University of Cape Town, Observatory, South Africa.
Fisher M; South African Tuberculosis Vaccine Initiative, University of Cape Town, Observatory, South Africa.
Magez S; Laboratory for Cellular and Molecular Immunology (CMIM), Department of Bioengineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium.; Department of Biochemistry and Microbiology, Ghent University, Gent, Belgium.; Laboratory for Biomedical Research, Department of Molecular Biotechnology, Environment Technology and Food Technology, Ghent University Global Campus, Incheon, Korea.
Jacobs M; Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Health Sciences Faculty, University of Cape Town, Observatory, South Africa.; National Health Laboratory Service, Cape Town, South Africa.; Infectious Disease Research Unit, University of Cape Town, Observatory, South Africa.
Keeton R; Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Health Sciences Faculty, University of Cape Town, Observatory, South Africa.
Pokaż więcej
Źródło:
Immunology [Immunology] 2022 Feb; Vol. 165 (2), pp. 219-233. Date of Electronic Publication: 2021 Dec 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
BCG Vaccine/*immunology
Host-Parasite Interactions/*immunology
Host-Pathogen Interactions/*immunology
Mycobacterium tuberculosis/*immunology
Tuberculosis/*prevention & control
Tuberculosis, Pulmonary/*prevention & control
Animals ; Apoptosis ; CD4 Lymphocyte Count ; Disease Models, Animal ; Female ; Humans ; Malaria/immunology ; Malaria/parasitology ; Memory T Cells/immunology ; Memory T Cells/metabolism ; Mice ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Tuberculosis Vaccines/immunology ; Vaccination
Czasopismo naukowe
Tytuł:
Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Autorzy:
Huang X; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Yan Y; National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Su B; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Xiao D; Rainbow Clinic of Beijing Jingcheng Skin Hospital, Beijing 100101, China.
Yu M; Department of AIDS/STD Control and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin 300011, China.
Jin X; AIDS Healthcare Foundation (AHF), Beijing 100088, China.
Duan J; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zhang X; Department of Public Health, The University of Tennessee, Knoxville, TN 37996, USA.
Zheng S; Department of Biostatistics and Epidemiology, East Tennessee State University, Johnson City, TN 70300, USA.
Fang Y; Department of Health and Physical Education, The Education University of Hong Kong, Hong Kong 200092, China.
Zhang T; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Tang W; University of North Carolina Project-China, Guangzhou 510095, China.
Wang L; National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Wang Z; JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 666888, China.
Xu J; Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen 518036, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jan 28; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 28.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
Antibodies, Viral/*blood
COVID-19/*epidemiology
COVID-19/*immunology
COVID-19 Vaccines/*immunology
HIV Infections/*epidemiology
SARS-CoV-2/*immunology
Vaccines, Inactivated/*immunology
Adolescent ; Adult ; Antibodies, Neutralizing/blood ; COVID-19/prevention & control ; COVID-19 Vaccines/administration & dosage ; China/epidemiology ; Cross-Sectional Studies ; Female ; HIV Infections/complications ; HIV Infections/immunology ; Humans ; Male ; Middle Aged ; Vaccination ; Vaccines, Inactivated/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł:
Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Autorzy:
Vajo Z; Department of Family Practice, Semmelweis University, 1085 Budapest, Hungary.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jan 20; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 20.
Typ publikacji:
Editorial
MeSH Terms:
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19 Vaccines/classification ; Humans
Opinia redakcyjna
Tytuł:
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
Autorzy:
Anywaine Z; Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.
Barry H; Centre MURAZ, Bobo-Dioulasso, Burkina Faso.
Anzala O; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya.
Mutua G; KAVI - Institute of Clinical Research University of Nairobi, Nairobi, Kenya.
Sirima SB; Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, Banfora, Burkina Faso.
Eholie S; Unit of Infectious and Tropical Diseases, BPV3, Treichville University Teaching Hospital, Abidjan, Côte d'Ivoire.
Kibuuka H; Makerere University - Walter Reed Project, Kampala, Uganda.
Bétard C; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.
Richert L; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France.
Lacabaratz C; Vaccine Research Institute (VRI), Créteil, France.; Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France.
McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Shukarev G; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Katwere M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Robinson C; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Gaddah A; Janssen Research & Development, Beerse, Belgium.
Heerwegh D; Janssen Research & Development, Beerse, Belgium.
Bockstal V; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Luhn K; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Leyssen M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Thiébaut R; Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria SISTM team; CHU Bordeaux; CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.; Vaccine Research Institute (VRI), Créteil, France.
Douoguih M; Janssen Vaccines and Prevention, Leiden, the Netherlands.
Pokaż więcej
Corporate Authors:
EBL2002 Study group
Źródło:
PLoS medicine [PLoS Med] 2022 Jan 11; Vol. 19 (1), pp. e1003865. Date of Electronic Publication: 2022 Jan 11 (Print Publication: 2022).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Immunity, Humoral*
Immunogenicity, Vaccine*
Ebola Vaccines/*adverse effects
Ebolavirus/*immunology
Hemorrhagic Fever, Ebola/*prevention & control
Adolescent ; Africa, Eastern ; Africa, Western ; Child ; Child, Preschool ; Female ; Humans ; Injections, Intramuscular ; Male
Czasopismo naukowe
Tytuł:
Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity.
Autorzy:
Claudino Formiga FF; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Silva CA; Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Pedrosa TDN; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Aikawa NE; Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Pasoto SG; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Garcia CC; Laboratory of Respiratory Virus and Measles, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Capão ASV; Laboratory of Respiratory Virus and Measles, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, Brazil.
Martins VAO; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Proença ACT; Department of Infectious and Parasitic Diseases, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Fuller R; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Yuki EFN; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Vendramini MBG; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Rosário DCD; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Brandão LMKR; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Sartori AMC; Department of Infectious and Parasitic Diseases, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Antonangelo L; Clinical Laboratory Division - Department of Pathology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Bonfá E; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Borba EF; Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Pokaż więcej
Źródło:
Lupus [Lupus] 2021 Oct; Vol. 30 (12), pp. 1915-1922. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji:
Journal Article
MeSH Terms:
Immunogenicity, Vaccine*
Influenza A Virus, H3N2 Subtype/*immunology
Influenza Vaccines/*administration & dosage
Lupus Erythematosus, Systemic/*prevention & control
Adult ; Antibodies, Viral ; Female ; Humans ; Influenza, Human/prevention & control ; Longitudinal Studies ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł:
Factors affecting the immunogenicity of influenza vaccines in human.
Autorzy:
Xu Q; School of Public Health (Shenzhen), Sun Yat-sen University-Shenzhen Campus, Shenzhen, Guangdong, China.
Wei H; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wen S; Clinical Research Center, Guangzhou First People's Hospital, the Second Affiliated Hospital of South China, University of Technology, Guangzhou, Guangdong, China.
Chen J; School of Public Health (Shenzhen), Sun Yat-sen University-Shenzhen Campus, Shenzhen, Guangdong, China.
Lei Y; School of Public Health (Shenzhen), Sun Yat-sen University-Shenzhen Campus, Shenzhen, Guangdong, China.
Cheng Y; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Huang W; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Wang D; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. .
Shu Y; School of Public Health (Shenzhen), Sun Yat-sen University-Shenzhen Campus, Shenzhen, Guangdong, China. .; Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical School, Beijing, China. .
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2023 Apr 06; Vol. 23 (1), pp. 211. Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Influenza Vaccines*
Influenza, Human*/prevention & control
Influenza A Virus, H1N1 Subtype*
Common Cold*
Humans ; Influenza B virus ; Influenza A Virus, H3N2 Subtype ; Vaccines, Inactivated ; Antibodies, Viral ; Hemagglutination Inhibition Tests ; Immunogenicity, Vaccine
Czasopismo naukowe
Tytuł:
Combined 13-valent pneumococcal conjugate and 23-valent pneumococcal polysaccharide vaccine regimens for adults with systemic lupus erythematosus: Does the sequence of pneumococcal vaccination affect immunogenicity responses? A single-center cohort study in Brazil.
Autorzy:
Rezende RPV; Rheumatology Division, Department of Clinical Medicine, Universidade Federal Fluminense, Niterói, Brazil.
Oliveira-Santos M; Department of Rheumatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Andrade LEC; Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.; Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
Klumb EM; Department of Rheumatology, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło:
Lupus [Lupus] 2023 Apr; Vol. 32 (5), pp. 694-703. Date of Electronic Publication: 2023 Jan 27.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Lupus Erythematosus, Systemic*
Pneumococcal Infections*/prevention & control
Adult ; Female ; Humans ; Male ; Antibodies, Bacterial ; Brazil ; Cohort Studies ; Double-Blind Method ; Immunogenicity, Vaccine ; Pneumococcal Vaccines ; Vaccination ; Vaccines, Conjugate
Czasopismo naukowe
Tytuł:
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates.
Autorzy:
Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gagne M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wagner DA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
O' Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Narpala SR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Flebbe DR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Andrew SF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Davis RL; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Flynn B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Johnston TS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Stringham CD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lai L; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Valentin D; BIOQUAL Inc., Rockville, MD 20850, USA.
Van Ry A; BIOQUAL Inc., Rockville, MD 20850, USA.
Flinchbaugh Z; BIOQUAL Inc., Rockville, MD 20850, USA.
Werner AP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Moliva JI; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sriparna M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Schmidt SD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Tucker C; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Choi A; Moderna Inc., Cambridge, MA 02139, USA.
Koch M; Moderna Inc., Cambridge, MA 02139, USA.
Bock KW; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Minai M; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nagata BM; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Alvarado GS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Henry AR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Laboune F; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Schramm CA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Choe M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Boyoglu-Barnum S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wei S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lamb E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nurmukhambetova ST; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Provost SJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Donaldson MM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Marquez J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Todd JM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Cook A; BIOQUAL Inc., Rockville, MD 20850, USA.
Dodson A; BIOQUAL Inc., Rockville, MD 20850, USA.
Pekosz A; Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Boritz E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Ploquin A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Doria-Rose N; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Pessaint L; BIOQUAL Inc., Rockville, MD 20850, USA.
Andersen H; BIOQUAL Inc., Rockville, MD 20850, USA.
Foulds KE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Misasi J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wu K; Moderna Inc., Cambridge, MA 02139, USA.
Carfi A; Moderna Inc., Cambridge, MA 02139, USA.
Nason MC; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mascola J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Moore IN; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Edwards DK; Moderna Inc., Cambridge, MA 02139, USA.
Lewis MG; BIOQUAL Inc., Rockville, MD 20850, USA.
Suthar MS; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Roederer M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
McDermott A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Douek DC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Dec 10; Vol. 374 (6573), pp. 1343-1353. Date of Electronic Publication: 2021 Oct 21.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
Vaccine Efficacy*
2019-nCoV Vaccine mRNA-1273/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
2019-nCoV Vaccine mRNA-1273/administration & dosage ; Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/analysis ; Antibodies, Viral/blood ; Bronchoalveolar Lavage Fluid/immunology ; Bronchoalveolar Lavage Fluid/virology ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Vaccines/administration & dosage ; Immunity, Mucosal ; Immunization, Secondary ; Macaca mulatta ; Memory B Cells/immunology ; Nose/immunology ; Nose/virology ; RNA, Viral/analysis ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/physiology ; T Follicular Helper Cells/immunology ; Th1 Cells/immunology ; Virus Replication
SCR Protocol:
COVID-19 vaccine booster shot
Czasopismo naukowe
Tytuł:
Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model.
Autorzy:
Sun W; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wang Z; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Animal Science and Technology, College of Veterinary and Medicine, Jilin Agricultural University, Changchun 130118, China.
Sun Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; Jilin Province Key Laboratory on Chemistry and Biology of Changbai Mountain Natural Drugs, School of Life Sciences, Northeast Normal University, Changchun 130024, China.
Li D; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.
Zhu M; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; Joint National Laboratory for Antibody Drug Engineering, School of Basic Medical Sciences, Henan University, Kaifeng 475001, China.
Zhao M; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wang Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Xu J; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; Key Laboratory of Animal Resistant Biology of Shandong, College of Life Sciences, Shandong Normal University, Jinan 250014, China.
Kong Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Li Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Feng N; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wang T; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Zhao Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Yang S; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Gao Y; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China.
Xia X; Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Dec 03; Vol. 13 (12). Date of Electronic Publication: 2021 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
Influenza Vaccines*/adverse effects
Influenza Vaccines*/immunology
Vaccine Efficacy*
Influenza A Virus, H5N1 Subtype/*immunology
Orthomyxoviridae Infections/*prevention & control
Adaptation, Physiological ; Animals ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Cold Temperature ; Dogs ; Female ; Hemagglutination Inhibition Tests ; Hemagglutinin Glycoproteins, Influenza Virus/chemistry ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Immunity, Cellular ; Immunity, Mucosal ; Influenza A Virus, H5N1 Subtype/genetics ; Influenza A Virus, H5N1 Subtype/physiology ; Influenza B virus/genetics ; Influenza B virus/immunology ; Madin Darby Canine Kidney Cells ; Mice ; Mice, Inbred BALB C ; Orthomyxoviridae Infections/immunology ; Recombinant Proteins ; Vaccines, Attenuated/immunology ; Virus Replication
Czasopismo naukowe
Tytuł:
Efficacy and immunogenicity of different BCG doses in BALB/c and CB6F1 mice when challenged with H37Rv or Beijing HN878.
Autorzy:
Khatri B; Bacteriology Division, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK. .
Keeble J; Bacteriology Division, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
Dagg B; Bacteriology Division, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
Kaveh DA; Department of Bacteriology, Animal and Plant Health Agency, Addlestone, Surrey, KT15 3NB, UK.
Hogarth PJ; Department of Bacteriology, Animal and Plant Health Agency, Addlestone, Surrey, KT15 3NB, UK.
Ho MM; Bacteriology Division, National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire, EN6 3QG, UK.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Dec 02; Vol. 11 (1), pp. 23308. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
BCG Vaccine/*immunology
Mycobacterium tuberculosis/*immunology
Tuberculosis/*immunology
Animals ; CD4-Positive T-Lymphocytes/immunology ; Disease Models, Animal ; Interferon-gamma ; Interleukin-2 ; Mice, Inbred BALB C ; Mice, Inbred Strains ; Tuberculosis/microbiology ; Tumor Necrosis Factor-alpha ; Mice
Czasopismo naukowe
Tytuł:
Allelic variants of full-length VAR2CSA, the placental malaria vaccine candidate, differ in antigenicity and receptor binding affinity.
Autorzy:
Renn JP; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Doritchamou JYA; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tentokam BCN; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Morrison RD; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Cowles MV; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Burkhardt M; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ma R; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Mahamar A; Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Attaher O; Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Diarra BS; Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Traore M; Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Dicko A; Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Tolia NH; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Fried M; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Duffy PE; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. .
Pokaż więcej
Źródło:
Communications biology [Commun Biol] 2021 Nov 19; Vol. 4 (1), pp. 1309. Date of Electronic Publication: 2021 Nov 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Immunogenicity, Vaccine*
Antigens, Protozoan/*immunology
Malaria Vaccines/*immunology
Plasmodium falciparum/*immunology
Female ; Humans ; Malaria, Falciparum/prevention & control ; Placenta/immunology ; Pregnancy ; Protein Binding
Czasopismo naukowe
Tytuł:
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
Autorzy:
Mateus J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Dan JM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Rydyznski Moderbacher C; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Lammers M; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Goodwin B; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA.
Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Oct 22; Vol. 374 (6566), pp. eabj9853. Date of Electronic Publication: 2021 Oct 22.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Immunogenicity, Vaccine*
Immunologic Memory*
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Spike Glycoprotein, Coronavirus/*immunology
2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19 Vaccines/administration & dosage ; Clinical Trials, Phase I as Topic ; Cross Reactions ; Humans ; Middle Aged ; Vaccination ; Young Adult
Czasopismo naukowe
Tytuł:
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Autorzy:
Formica N; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Mallory R; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Albert G; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Robinson M; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Plested JS; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Cho I; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Robertson A; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Dubovsky F; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Glenn GM; Novavax, Inc., Gaithersburg, Maryland, United States of America.
Pokaż więcej
Corporate Authors:
2019nCoV-101 Study Group
Źródło:
PLoS medicine [PLoS Med] 2021 Oct 01; Vol. 18 (10), pp. e1003769. Date of Electronic Publication: 2021 Oct 01 (Print Publication: 2021).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Dose-Response Relationship, Immunologic ; Female ; Humans ; Immunoglobulin G/immunology ; Male ; Middle Aged ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology ; Young Adult
Czasopismo naukowe
Tytuł:
Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice.
Autorzy:
Skandorff, Isabella (AUTHOR)
Ragonnaud, Emeline (AUTHOR)
Gille, Jasmin (AUTHOR)
Andersson, Anne-Marie (AUTHOR)
Schrödel, Silke (AUTHOR)
Duvnjak, Lara (AUTHOR)
Turner, Louise (AUTHOR)
Thirion, Christian (AUTHOR)
Wagner, Ralf (AUTHOR)
Holst, Peter Johannes (AUTHOR)
Pokaż więcej
Źródło:
International Journal of Molecular Sciences. Jun2023, Vol. 24 Issue 12, p9972. 22p.
Czasopismo naukowe
Tytuł:
A recombinant rabies virus chimera expressing the DC-targeting molecular MAB2560 shows enhanced vaccine immunogenicity through activation of dendritic cells.
Autorzy:
Gong, Zhiyuan (AUTHOR)
Huang, Pei (AUTHOR)
Jin, Hongli (AUTHOR)
Bai, Yujie (AUTHOR)
Li, Hailun (AUTHOR)
Qian, Meichen (AUTHOR)
Sun, Jingxuan (AUTHOR)
Jiao, Cuicui (AUTHOR)
Zhang, Mengyao (AUTHOR)
Li, Yuanyuan (AUTHOR)
Zhang, Haili (AUTHOR)
Wang, Hualei (AUTHOR)
Pokaż więcej
Źródło:
PLoS Neglected Tropical Diseases. 4/24/2023, Vol. 16 Issue 4, p1-23. 23p.
Czasopismo naukowe
Tytuł:
Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever.
Autorzy:
Albaqami, Faisal F. (AUTHOR)
Altharawi, Ali (AUTHOR)
Althurwi, Hassan N. (AUTHOR)
Alharthy, Khalid M. (AUTHOR)
Qasim, Muhammad (AUTHOR)
Muhseen, Ziyad Tariq (AUTHOR)
Tahir ul Qamar, Muhammad (AUTHOR)
Pokaż więcej
Źródło:
BioMed Research International. 4/17/2023, p1-18. 18p.
Czasopismo naukowe
Tytuł:
Immunogenicity of measles-rubella vaccine administered under India’s Universal Immunization Programme in the context of measles–rubella elimination goal: A longitudinal study.
Autorzy:
Verma, Santosh Kumar
Shah, Dheeraj
Singh, Aaradhana
Singh, Praveen Kumar
Das, Shukla
Gupta, Piyush
Pokaż więcej
Źródło:
Indian Journal of Medical Research. Apr2023, Vol. 157 Issue 4, p250-258. 9p.
Czasopismo naukowe
Tytuł:
Antigenicity and Immunogenicity Analysis of the E. coli Expressed FMDV Structural Proteins; VP1, VP0, VP3 of the South African Territories Type 2 Virus.
Autorzy:
Li G; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Wubshet AK; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.; Department of Basic and Diagnostic Sciences, College of Veterinary Science, Mekelle University, Tigray 280, Ethiopia.
Ding Y; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Li Q; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Dai J; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Wang Y; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Hou Q; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Chen J; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Ma B; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Szczotka-Bochniarz A; Department of Swine Diseases, National Veterinary Research Institute, 57 Partyzantow, 24-100 Puławy, Poland.
Szathmary S; RT-Europe Research Center, H-9200 Mosonmagyarovar, Hungary.
Zhang Y; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Zhang J; State Key Laboratory of Veterinary Etiological Biology, National/OIE Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 May 27; Vol. 13 (6). Date of Electronic Publication: 2021 May 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
Capsid Proteins/*genetics
Escherichia coli/*genetics
Foot-and-Mouth Disease/*prevention & control
Foot-and-Mouth Disease Virus/*genetics
Foot-and-Mouth Disease Virus/*immunology
Viral Structural Proteins/*genetics
Viral Vaccines/*immunology
Animals ; Capsid Proteins/immunology ; Female ; Foot-and-Mouth Disease/immunology ; Foot-and-Mouth Disease/virology ; Foot-and-Mouth Disease Virus/chemistry ; Immunization ; Mice ; Mice, Inbred BALB C ; Recombinant Proteins/genetics ; South Africa ; Specific Pathogen-Free Organisms ; Viral Structural Proteins/classification ; Viral Structural Proteins/immunology ; Viral Vaccines/genetics
Czasopismo naukowe
Tytuł:
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
Autorzy:
Corbett KS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nason MC; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Flach B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gagne M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
O'Connell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Johnston TS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Shah SN; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Edara VV; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Floyd K; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
Lai L; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
McDanal C; Department of Surgery, Duke University Medical Center, Durham, NC 27708, USA.
Francica JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Flynn B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wu K; Moderna Inc., Cambridge, MA 02139, USA.
Choi A; Moderna Inc., Cambridge, MA 02139, USA.
Koch M; Moderna Inc., Cambridge, MA 02139, USA.
Abiona OM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Werner AP; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Moliva JI; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Andrew SF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Donaldson MM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Fintzi J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Flebbe DR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lamb E; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Noe AT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nurmukhambetova ST; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Provost SJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Cook A; Bioqual Inc., Rockville, MD 20850, USA.
Dodson A; Bioqual Inc., Rockville, MD 20850, USA.
Faudree A; Bioqual Inc., Rockville, MD 20850, USA.
Greenhouse J; Bioqual Inc., Rockville, MD 20850, USA.
Kar S; Bioqual Inc., Rockville, MD 20850, USA.
Pessaint L; Bioqual Inc., Rockville, MD 20850, USA.
Porto M; Bioqual Inc., Rockville, MD 20850, USA.
Steingrebe K; Bioqual Inc., Rockville, MD 20850, USA.
Valentin D; Bioqual Inc., Rockville, MD 20850, USA.
Zouantcha S; Bioqual Inc., Rockville, MD 20850, USA.
Bock KW; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Minai M; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nagata BM; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
van de Wetering R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Boyoglu-Barnum S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Leung K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Todd JM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Alvarado GS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Andersen H; Bioqual Inc., Rockville, MD 20850, USA.
Foulds KE; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Edwards DK; Moderna Inc., Cambridge, MA 02139, USA.
Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Moore IN; Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lewis MG; Bioqual Inc., Rockville, MD 20850, USA.
Carfi A; Moderna Inc., Cambridge, MA 02139, USA.
Montefiori D; Department of Surgery, Duke University Medical Center, Durham, NC 27708, USA.
Suthar MS; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.; Department of Microbiology and Immunology, Atlanta, GA 30329, USA.
McDermott A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Roederer M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Douek DC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2021 Sep 17; Vol. 373 (6561), pp. eabj0299. Date of Electronic Publication: 2021 Sep 17.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Immunogenicity, Vaccine*
Antibodies, Neutralizing/*blood
Antibodies, Viral/*blood
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
2019-nCoV Vaccine mRNA-1273 ; Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Antibody Affinity ; Bronchoalveolar Lavage Fluid/immunology ; Bronchoalveolar Lavage Fluid/virology ; CD4-Positive T-Lymphocytes/immunology ; COVID-19/immunology ; COVID-19/virology ; Female ; Immunization Schedule ; Immunization, Passive ; Immunization, Secondary ; Immunoglobulin G/immunology ; Immunologic Memory ; Lung/immunology ; Lung/virology ; Macaca mulatta ; Male ; Mesocricetus ; Nasal Mucosa/immunology ; Nasal Mucosa/virology ; SARS-CoV-2/physiology ; Spike Glycoprotein, Coronavirus/immunology ; Vaccination ; Vaccine Potency ; Virus Replication
Czasopismo naukowe
Tytuł:
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
Autorzy:
Geng Q; Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, Minnesota, United States of America.; Center for Coronavirus Research, University of Minnesota, Saint Paul, Minnesota, United States of America.
Tai W; Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Baxter VK; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.; Division of Comparative Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Shi J; Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Wan Y; Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, Minnesota, United States of America.; Center for Coronavirus Research, University of Minnesota, Saint Paul, Minnesota, United States of America.
Zhang X; Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Montgomery SA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Taft-Benz SA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Anderson EJ; Division of Comparative Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Knight AC; Division of Comparative Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Dinnon KH 3rd; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Leist SR; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Baric RS; Division of Comparative Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Shang J; Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, Minnesota, United States of America.; Center for Coronavirus Research, University of Minnesota, Saint Paul, Minnesota, United States of America.
Hong SW; Center for Immunology, Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, United States of America.
Drelich A; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Tseng CK; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.
Jenkins M; Center for Immunology, Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, United States of America.
Heise M; Division of Comparative Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America.; Rapidly Emerging Antiviral Drug Development Initiative, University of North Carolina, Chapel Hill, North Carolina, United States of America.; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Du L; Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, United States of America.
Li F; Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, Minnesota, United States of America.; Center for Coronavirus Research, University of Minnesota, Saint Paul, Minnesota, United States of America.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2021 Sep 07; Vol. 17 (9), pp. e1009897. Date of Electronic Publication: 2021 Sep 07 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Immunogenicity, Vaccine*
COVID-19/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Nanoparticles/*therapeutic use
Angiotensin-Converting Enzyme 2/immunology ; Animals ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Disease Models, Animal ; Drug Design ; Female ; HEK293 Cells ; Humans ; Lung/virology ; Mice ; Mice, Inbred BALB C ; Protein Domains/immunology
Czasopismo naukowe
Tytuł:
Identification of anti-horn fly vaccine antigen candidates using a reverse vaccinology approach.
Autorzy:
Domingues LN; USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville, TX, USA. .; Texas A&M University, Department of Entomology, 2475 TAMU, College Station, TX, USA. .
Bendele KG; USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville, TX, USA. .
Halos L; Boehringer Ingelheim Animal Health, 29 Avenue Tony Garnier, 69007, Lyon, France.; Bill and Melinda Gates Foundation, Seattle, WA, USA.
Moreno Y; Boehringer Ingelheim Animal Health, Pharmaceutical Discovery and Research, 3239 Satellite Blvd. Bldg. 600, Duluth, GA, USA.
Epe C; Boehringer Ingelheim Animal Health, Pharmaceutical Discovery and Research, 3239 Satellite Blvd. Bldg. 600, Duluth, GA, USA.
Figueiredo M; Boehringer Ingelheim Animal Health, Pharmaceutical Discovery and Research, 3239 Satellite Blvd. Bldg. 600, Duluth, GA, USA.
Liebstein M; Boehringer Ingelheim Animal Health Missouri Research Center, 6498 Jade Rd, Fulton, MO, USA.
Guerrero FD; USDA-ARS Knipling-Bushland U. S. Livestock Insects Research Lab, 2700 Fredericksburg Road, Kerrville, TX, USA.
Pokaż więcej
Źródło:
Parasites & vectors [Parasit Vectors] 2021 Sep 03; Vol. 14 (1), pp. 442. Date of Electronic Publication: 2021 Sep 03.
Typ publikacji:
Journal Article
MeSH Terms:
Immunogenicity, Vaccine*
Cattle Diseases/*prevention & control
Muscidae/*genetics
Muscidae/*immunology
Vaccines/*immunology
Vaccinology/*methods
Animals ; Antigens/genetics ; Antigens/immunology ; Cattle ; Female ; Male ; Polymerase Chain Reaction/methods ; Reverse Transcription
Czasopismo naukowe
Tytuł:
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
Autorzy:
van Doremalen N; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Fischer RJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Schulz JE; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Holbrook MG; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Smith BJ; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Lovaglio J; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Petsch B; CureVac AG, 72076 Tuebingen, Germany.
Munster VJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Aug 19; Vol. 13 (8). Date of Electronic Publication: 2021 Aug 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Intramural
MeSH Terms:
Immunization, Secondary*
Immunogenicity, Vaccine*
Antibodies, Viral/*blood
COVID-19 Vaccines/*immunology
SARS-CoV-2/*immunology
Vaccines, Synthetic/*immunology
Animals ; Antibodies, Neutralizing/blood ; COVID-19 Vaccines/administration & dosage ; Immunity, Cellular ; Immunization Schedule ; Macaca mulatta ; Male ; Spike Glycoprotein, Coronavirus/immunology ; T-Lymphocytes/immunology ; Vaccines, Synthetic/administration & dosage ; mRNA Vaccines
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies